Compare Annaly Capital Management, Inc. (NLY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Annaly Capital Management, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Annaly Capital Management, Inc. trades at $18.1 (market cap $13.77B), while Vertex Pharmaceuticals Incorporated trades at $513.62 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 9.3× Annaly Capital Management, Inc.'s market cap, and Annaly Capital Management, Inc. pays a 16.42% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Annaly Capital Management, Inc. for 92 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| NLY | VRTX | |
|---|---|---|
Market Cap | $13.77B | $127.55B |
Volume | 21,283,879 | 1,487,944 |
Sector | Real Estate | Health |
52-Week High | $24.40 | $557.96 |
52-Week Low | $17.93 | $407.37 |
Typical Hold Time | 92 Days | 120 Days |
Enterprise Value | $135.80B | $121.68B |
Dividend Yield | 16.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NLY trades at $17.93, down 2.66% on the day, with a bearish technical signal driven by moving averages. The stock offers a high dividend yield near 15% and trades below book value (P/B 0.91). Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $0.79 surpassing the $0.751 forecast. The company announced a $0.75 quarterly dividend payable in October 2026.
The outlook balances a discounted valuation and strong dividend against interest rate sensitivity and recent price weakness. Upside exists if earnings growth continues, but the stock faces headwinds from rising mortgage rates and bearish technical momentum. Analyst consensus is bullish with a $22.00 price target, suggesting significant potential appreciation.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
